Key Points Wall Street analysts are modestly bullish on the stock. However, the expanding GLP-1 market and Lilly's strong patents suggest it can regain momentum. 10 stocks we like better than Eli Lilly › Eli Lilly (NYSE: LLY) has had an impressive run over the past few years. The stock is up 410% over the last five years and 58% over the past 52 weeks. Its performance this year, however, has been a bit more modest, up just 10.1%. So, it's underperforming the broader market, as measured by the S&P 500 (SNPINDEX: ^GSPC) , which gained around 12.5% so far in 2026. I think the deceleration in the stock's climb this year is probably due to its run-up over the past few years, which has made it expensive.
We show the main point publicly. Create a free account to continue reading the full article, save it, discuss it, and connect it with market and OSINT context.